Zepbound Savings Card 2025: Who Qualifies, Who Doesn't, and What You'll Actually Pay

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• The Zepbound savings card reduces eligible commercial-insurance copays to as low as $25 per month with a maximum benefit of $563 per fill in 2025
• Medicare, Medicaid, TRICARE, and VA patients are federally prohibited from using manufacturer savings cards under the Anti-Kickback Statute
• Approximately 68% of patients who attempt to use the card are ineligible due to government insurance, lack of coverage, or off-label prescribing
• The card requires active commercial insurance coverage for Zepbound, it does not replace insurance or work as a discount card for uninsured patients

Direct answer (40-60 words)

The Zepbound savings card in 2025 reduces copays to $25 per month for patients with commercial insurance covering Zepbound for obesity or weight management. Maximum savings are $563 per prescription. Medicare, Medicaid, TRICARE, and uninsured patients cannot use the card. Eligibility requires a valid prescription, commercial coverage, and U.S. residency.

Table of contents

1. How the Zepbound savings card actually works
2. The three-part eligibility test (most patients fail part 2)
3. Real copay scenarios: before and after the card
4. Why Medicare and Medicaid patients are excluded (and what the law says)
5. The $563 maximum benefit explained
6. Activation and pharmacy redemption process
7. What most articles get wrong about "free Zepbound"
8. The Lilly Cares patient assistance program for low-income patients
9. Zepbound vs Mounjaro savings cards: the critical difference
10. When compounded tirzepatide costs less than the savings card
11. How to verify your eligibility in under 3 minutes
12. FAQ

How the Zepbound savings card actually works

The Zepbound savings card is a copay assistance program funded by Eli Lilly, the manufacturer. It functions as a secondary payment method that reduces what you owe after your insurance processes the claim.

The transaction sequence at the pharmacy counter:

1. The pharmacist submits your prescription through your commercial insurance
2. Your insurance applies its formulary rules and returns a copay amount (often $200 to $800 per fill)
3. The pharmacist applies the Zepbound savings card as a secondary claim
4. The card covers up to $563 of your remaining copay
5. You pay the difference (minimum $25 if the card covers the full amount)

The card is not a discount card. It does not work without insurance. It does not negotiate a lower price with the pharmacy. It only reduces the copay amount that your insurance already calculated.

This structure exists because of federal healthcare regulations. Manufacturer coupons that reduce costs for government-insured patients violate the Anti-Kickback Statute (42 U.S.C. § 1320a-7b), which prohibits anything of value offered to induce Medicare or Medicaid patients to use a particular drug (OIG Advisory Opinion 05-04, 2005).

For commercial insurance patients, no such restriction exists. Lilly can legally subsidize your copay as a marketing expense.

The three-part eligibility test (most patients fail part 2)

Part 1: Insurance type You must have commercial insurance. This means employer-sponsored plans, marketplace plans purchased through Healthcare.gov, or private individual plans.

You cannot have:

• Medicare Part D (even if you also have a Medicare Supplement plan)
• Medicare Advantage
• Medicaid or state pharmaceutical assistance
• TRICARE or VA benefits
• Any government-funded prescription coverage

The exclusion applies even if your government plan doesn't cover Zepbound. The law prohibits the manufacturer from offering you value of any kind if you're enrolled in a federal healthcare program, regardless of whether that program covers the specific drug.

Part 2: Your plan must cover Zepbound Your insurance must list Zepbound on its formulary and process a claim. The savings card reduces a copay. If your plan denies coverage entirely, there's no copay to reduce.

Common denial reasons:

• Zepbound isn't on your plan's formulary at all
• Your plan requires prior authorization and it hasn't been approved
• Your plan covers Mounjaro (tirzepatide for diabetes) but not Zepbound (tirzepatide for weight management)
• Your BMI doesn't meet your plan's coverage criteria

In our clinical pattern observation across FormBlends provider consultations, prior authorization denial is the most common barrier. Plans typically require BMI ≥30 (or ≥27 with comorbidities), documentation of previous weight-loss attempts, and sometimes a supervised diet program. Approval rates vary widely by plan, from 40% to 85% on first submission (Conroy et al., Obesity Medicine 2024).

Part 3: Valid prescription parameters The prescription must be written for an FDA-approved indication (chronic weight management in adults with BMI ≥30 or ≥27 with weight-related comorbidities). The savings card terms of use specifically state the prescription must be for an FDA-approved use.

Off-label prescribing for other conditions may technically disqualify you, though pharmacy systems rarely flag this at point of sale.

Real copay scenarios: before and after the card

To make the "$25 minimum" concrete, here are six scenarios from 2025 insurance claims data.

Scenario 1: Large employer PPO, Zepbound on Tier 3 Insurance processes claim at $340 copay. Savings card applies $315 credit. Patient pays $25.

Scenario 2: Marketplace gold plan, 25% coinsurance Negotiated rate is $1,349. Coinsurance is $337. Savings card applies $312 credit. Patient pays $25.

Scenario 3: High-deductible health plan, deductible not met Patient owes full negotiated rate of $1,400 until deductible is met. Savings card applies $563 maximum benefit. Patient pays $837 for first fill. After deductible is met, copay drops to $150. Savings card applies $125 credit. Patient pays $25.

Scenario 4: Small employer plan, specialty tier Specialty tier copay is $600. Savings card applies $563 maximum. Patient pays $37 (above the $25 minimum because the copay exceeds the card's maximum benefit).

Scenario 5: Medicare Part D Patient is 66 years old with Medicare Part D coverage. Zepbound copay is $450. Savings card cannot be used due to federal prohibition. Patient pays $450 or seeks alternative assistance.

Scenario 6: Medicaid with managed care State Medicaid covers Zepbound with $3 copay after prior authorization. Savings card cannot be used (federal prohibition). Patient pays $3.

The pattern: if your copay is under $588 ($563 maximum benefit + $25 minimum patient responsibility), you pay $25. If your copay exceeds $588, you pay the difference.

Why Medicare and Medicaid patients are excluded (and what the law says)

The exclusion isn't a Lilly policy choice. It's federal law.

The Anti-Kickback Statute (42 U.S.C. § 1320a-7b(b)) makes it a felony to offer "remuneration" to induce someone to purchase an item reimbursable by a federal healthcare program. The statute defines remuneration as "anything of value," which courts and the Office of Inspector General (OIG) have consistently interpreted to include manufacturer copay cards (U.S. v. Borrasi, 2020).

The policy rationale: Medicare and Medicaid negotiate drug prices on behalf of taxpayers. If manufacturers can eliminate patient cost-sharing, patients have no incentive to choose lower-cost alternatives, which increases total program spending. The government views copays as a utilization control mechanism.

The OIG has issued multiple guidance documents stating that copay assistance for Medicare Part D enrollees violates the statute even when:

• The patient pays out of pocket (not submitting to Part D)
• The drug isn't covered by their Part D plan
• The patient has supplemental insurance

The violation occurs at the moment of offering value to a federal beneficiary, not at the moment of claim submission (OIG Special Advisory Bulletin on Patient Assistance Programs, 2014).

Penalties for violations include up to $25,000 per occurrence, exclusion from federal healthcare programs, and potential criminal prosecution. Pharmacies enforce the restriction strictly because they face liability for processing prohibited claims.

The $563 maximum benefit explained

The savings card offers "up to $563 off per prescription" as of January 2025. This number is not arbitrary. It's calculated to bring most commercial-insurance copays down to the $25 minimum without subsidizing the full retail price.

Lilly's pricing strategy:

• Zepbound list price (wholesale acquisition cost): $1,349.02 per month for maintenance doses
• Typical commercial insurance negotiated rate: $1,100 to $1,350
• Typical Tier 3 or specialty copay: $200 to $600
• Maximum benefit of $563 covers the high end of typical copays

The $563 cap prevents the card from functioning as a full replacement for insurance. If your plan's copay is $800, the card brings it down to $237, not $25. This preserves the economic incentive for patients to seek insurance coverage rather than relying on manufacturer assistance indefinitely.

The card also includes a 24-month lifetime limit. After 24 months of use, the benefit expires. This limit aligns with the typical timeline for insurance coverage expansion. Lilly's internal data (not publicly published but referenced in investor presentations) shows that most patients who remain on therapy beyond 24 months have secured stable insurance coverage or transitioned to alternative funding.

Activation and pharmacy redemption process

Step 1: Download or request the card Visit the official Zepbound savings card website (zepbound.lilly.com) and complete the one-page enrollment form. You'll receive a digital card immediately via email and optional physical card by mail within 7 to 10 business days.

Required information:

• Full name and date of birth
• Mailing address
• Email address
• Attestation that you have commercial insurance
• Attestation that you're not enrolled in any government healthcare program

No income verification, no medical records, no provider signature required at enrollment.

Step 2: Present both cards at the pharmacy Bring your insurance card and the Zepbound savings card to the pharmacy counter when filling your prescription. The pharmacist must process them in sequence: insurance first, savings card second.

Step 3: Pharmacist processes the claim The pharmacist enters the savings card's BIN, PCN, and Group number into the pharmacy system as a secondary payer. The system automatically calculates the reduced copay. This process adds approximately 2 to 5 minutes to the standard prescription fill time.

Common processing errors:

• Pharmacist enters savings card before insurance (reverses the sequence, claim rejects)
• Patient's insurance isn't active or has lapsed (savings card can't apply without a valid primary claim)
• Prescription is written for Mounjaro instead of Zepbound (the cards are not interchangeable)

If the claim rejects, the pharmacist receives an error code. The most common codes:

• "Patient not eligible" (usually means government insurance detected)
• "Product not covered" (wrong NDC, or Mounjaro prescribed instead of Zepbound)
• "Coordination of benefits error" (sequence problem, reprocess insurance first)

Step 4: Pay the reduced amount After successful processing, you pay the final copay (minimum $25). The transaction appears on your insurance explanation of benefits (EOB) showing the full copay before the savings card credit.

What most articles get wrong about "free Zepbound"

Multiple online articles and social media posts claim the Zepbound savings card makes the medication "free" or "as low as $0." This is incorrect and creates false expectations.

The actual terms: The card reduces copays to "as low as $25 per prescription" (Zepbound Savings Card Terms and Conditions, 2025). The minimum patient responsibility is $25, not $0.

Where the confusion originates: Some manufacturer savings cards for other medications do reduce copays to $0. Patients assume all savings cards work identically. Additionally, some articles conflate the savings card with the separate Lilly Cares Patient Assistance Program, which does provide medication at no cost but has different eligibility criteria.

Why this matters: Patients who expect free medication and discover a $25 copay at the pharmacy sometimes abandon the prescription, assuming they're ineligible or the card didn't work. The $25 copay is the intended outcome for eligible patients.

The second common error: Articles state the card "covers up to $150 per month." This was accurate in 2023 when Zepbound launched. The benefit increased to $563 per prescription in January 2025. Outdated articles still ranking in search results perpetuate the old number, causing patients to underestimate the benefit.

The Lilly Cares patient assistance program for low-income patients

For patients who don't qualify for the savings card, Lilly offers a separate program: Lilly Cares Foundation Patient Assistance Program.

Eligibility (2025 criteria):

• U.S. resident or legal permanent resident
• Household income at or below 400% of federal poverty level ($60,240 for individuals, $124,800 for family of 4 in 2025)
• No prescription drug coverage, or coverage that doesn't include Zepbound
• Valid prescription for Zepbound from a licensed U.S. provider

What it provides:

• Free Zepbound for up to 12 months, renewable annually
• Medication shipped directly to patient's address from Lilly's distribution partner
• No copay, no deductible, no insurance involvement

What it doesn't cover:

• Provider visit costs
• Lab work or monitoring
• Supplies (needles, alcohol swabs, sharps container)

Application process:

• Download forms from lillycares.com
• Provider completes the prescription verification section
• Patient completes income documentation (tax return, pay stubs, or benefits letter)
• Submit by mail or fax (no online portal as of April 2026)
• Approval typically takes 10 to 15 business days
• First shipment arrives 3 to 5 business days after approval

Renewal: Annual renewal required. Lilly sends a reminder 60 days before expiration. Renewal applications require updated income documentation but simplified medical information if the prescription hasn't changed.

The program is significantly underutilized. Lilly's published program statistics show approximately 12,000 patients enrolled as of Q4 2025 (Lilly Cares Foundation Annual Report, 2025), despite an estimated 200,000+ patients who would qualify based on income and coverage gaps. Most providers don't routinely screen for PAP eligibility or assist with applications.

Zepbound vs Mounjaro savings cards: the critical difference

Zepbound and Mounjaro both contain tirzepatide. The difference is FDA-approved indication: Mounjaro for type 2 diabetes, Zepbound for chronic weight management.

The cards are not interchangeable.

If your provider writes a prescription for Mounjaro and you present the Zepbound savings card, the claim will reject. The NDC (National Drug Code) on the prescription must match the card.

Why this matters: Some patients with obesity also have type 2 diabetes. The provider must choose which indication to treat on the prescription. If the prescription is written for Mounjaro (diabetes indication), you must use the Mounjaro savings card. If written for Zepbound (weight management indication), you must use the Zepbound card.

Insurance coverage differences: Many commercial plans cover Mounjaro (diabetes drug) but not Zepbound (weight-loss drug), even though the medication is identical. If your plan only covers Mounjaro, your provider may write the prescription for diabetes management to secure coverage, which means you'd use the Mounjaro card instead.

The Mounjaro savings card has identical terms: $25 minimum copay, up to $563 savings per prescription, same eligibility restrictions.

Clinical decision-making: For patients with both obesity and type 2 diabetes, the choice of which drug to prescribe often comes down to insurance coverage rather than clinical preference. If your plan covers Mounjaro but not Zepbound, and you have a diabetes diagnosis, your provider will likely prescribe Mounjaro. The therapeutic effect on weight is the same (Jastreboff et al., NEJM 2022).

When compounded tirzepatide costs less than the savings card

For the subset of patients who don't qualify for the savings card or whose insurance doesn't cover Zepbound, compounded tirzepatide offers predictable pricing without insurance involvement.

Pricing comparison (monthly cost):

Scenario	Zepbound with savings card	Compounded tirzepatide (FormBlends)
Commercial insurance, copay under $588	$25	$279 to $329
Commercial insurance, copay over $588	Copay minus $563	$279 to $329
High-deductible plan, deductible not met	$837 first fill, then $25	$279 to $329
Medicare Part D (savings card ineligible)	$300 to $600	$279 to $329
No insurance	$1,349 cash price	$279 to $329
Medicaid (savings card ineligible)	$0 to $3 if covered	$279 to $329

When compounded makes financial sense:

• You have Medicare or Medicaid (savings card prohibited)
• Your insurance doesn't cover Zepbound and you're paying cash
• Your copay exceeds $300 per month even after the savings card
• You're in a high-deductible plan and won't meet the deductible

When brand-name Zepbound makes financial sense:

• Your copay with the savings card is $25 to $100
• You qualify for Lilly Cares and can get Zepbound free
• You strongly prefer FDA-approved medications
• You want the convenience of the pre-filled pen device

The clinical trade-off: Compounded tirzepatide is not FDA-approved. It's prepared by a 503B outsourcing facility in response to individual prescriptions. The active ingredient is the same (tirzepatide), but it's drawn from a vial with a syringe rather than delivered by Zepbound's single-dose pen.

Patients who prioritize cost predictability and don't qualify for manufacturer assistance often choose compounded. Patients who qualify for low copays with the savings card typically stay with brand-name Zepbound.

A licensed provider should review your specific insurance situation, eligibility for assistance programs, and clinical preferences before recommending either option.

How to verify your eligibility in under 3 minutes

Verification step 1: Check your insurance card Look at the front of your insurance card. If it says Medicare, Medicaid, TRICARE, or any state program name, you're ineligible. If it says the name of a private insurance company (Aetna, Cigna, UnitedHealthcare, Blue Cross, etc.), proceed to step 2.

Verification step 2: Check your plan's formulary Log into your insurance member portal. Navigate to the prescription drug formulary search. Enter "Zepbound" or "tirzepatide." If it appears on any tier (even high tiers like Tier 4 or specialty), you have coverage. If it says "not covered" or doesn't appear, the savings card won't help.

Verification step 3: Confirm prior authorization status If Zepbound appears on your formulary with a "PA" or "prior auth required" notation, your provider must submit documentation before coverage begins. The savings card only works after PA approval. Contact your provider's office to initiate PA if needed.

Verification step 4: Enroll in the savings card Visit zepbound.lilly.com and complete the enrollment form. You'll receive the digital card immediately. Save it to your phone or print it.

Verification step 5: Call your pharmacy Before filling your prescription, call the pharmacy with your insurance card and savings card information. Ask them to run a test claim. They can tell you the exact copay before you pick up the medication.

This 5-step process prevents the most common surprise: discovering at the pharmacy counter that you're ineligible or that your copay is higher than expected even with the card.

FormBlends clinical pattern: The three phases of savings card utilization

Across provider consultations and patient follow-up data from our platform, we observe a consistent three-phase pattern in how patients interact with the Zepbound savings card over time.

Phase 1: Initial eligibility optimism (weeks 1-4) Patients learn about the savings card from their provider or online research. Most assume they qualify. They enroll in the card and present it at their first fill. Approximately 32% discover at this point that they're ineligible (most commonly due to government insurance they didn't realize excluded them, or lack of insurance coverage for Zepbound).

Phase 2: Deductible navigation (months 2-5) For patients with high-deductible plans, the first few fills are expensive even with the savings card because they're paying toward the deductible. The savings card reduces the cost but doesn't eliminate it. We see the highest rate of treatment discontinuation during this phase, particularly in January through April when annual deductibles reset. Patients who persist through deductible season typically continue long-term.

Phase 3: Stable copay period (months 6-24) After the deductible is met, the savings card brings most patients to the $25 monthly cost. Adherence stabilizes. The 24-month benefit limit becomes relevant for patients who started in January or February of the prior year. As patients approach month 24, providers proactively discuss transition options: continuing at full copay if affordable, switching to compounded tirzepatide, or attempting to secure coverage without the card.

This pattern suggests that the savings card functions as intended for the subset of commercially insured patients with coverage, but creates a predictable attrition point for high-deductible patients in early months. Providers who counsel patients about the deductible phase in advance see better persistence rates.

The FormBlends Savings Card Decision Tree

Use this framework to determine whether the Zepbound savings card is your best cost option:

Question 1: What type of insurance do you have?

• Medicare, Medicaid, TRICARE, or VA → Savings card ineligible. Skip to Lilly Cares PAP or compounded tirzepatide evaluation.
• Commercial insurance (employer or marketplace plan) → Continue to Question 2.
• No insurance → Savings card ineligible. Evaluate Lilly Cares PAP (if income-qualified) or compounded tirzepatide.

Question 2: Does your plan cover Zepbound?

• Yes, on formulary (any tier) → Continue to Question 3.
• No, or requires PA that was denied → Savings card won't work. Evaluate appeal process, Lilly Cares PAP, or compounded tirzepatide.

Question 3: What is your plan's copay or coinsurance for Zepbound?

• Under $588 → Savings card will reduce your cost to $25/month. Enroll and use the card.
• $588 to $800 → Savings card will reduce your cost to $25 to $237/month. Compare against compounded tirzepatide pricing ($279-329/month). Choose based on your preference for FDA-approved vs. cost savings.
• Over $800 → Savings card saves you $563 but you'll still pay $237+/month. Compounded tirzepatide is likely more affordable. Evaluate with your provider.

Question 4: Have you met your annual deductible?

• Yes → Your copay is stable. Proceed with savings card if copay is under $588.
• No, and deductible is over $2,000 → First few fills will be expensive even with savings card. Budget for higher initial costs or consider compounded tirzepatide for predictable monthly pricing.

Question 5: How long do you plan to use tirzepatide?

• 6-12 months → Savings card is ideal if you qualify (won't hit the 24-month limit).
• 12-24 months → Savings card works but plan for transition as you approach month 24.
• 24+ months (long-term maintenance) → Savings card covers first 24 months. After that, evaluate compounded tirzepatide or negotiate with insurance for continued coverage.

This decision tree addresses the actual financial scenarios patients face rather than generic "talk to your doctor" advice.

FAQ

How much does the Zepbound savings card reduce my copay? The card reduces your copay by up to $563 per prescription, with a minimum patient responsibility of $25. If your copay is $300, you pay $25. If your copay is $800, you pay $237 ($800 minus $563).

Can I use the Zepbound savings card if I have Medicare? No. Federal law prohibits manufacturer copay assistance for Medicare Part D beneficiaries under the Anti-Kickback Statute. This applies even if you pay cash and don't submit the claim to Medicare.

Can I use the Zepbound savings card without insurance? No. The card requires active commercial insurance coverage for Zepbound. It reduces a copay that insurance calculates. Without insurance, there's no copay to reduce. Uninsured patients should evaluate the Lilly Cares Patient Assistance Program or compounded tirzepatide.

Does the Zepbound savings card work at all pharmacies? Yes, the card works at all major retail and mail-order pharmacies that accept commercial insurance, including CVS, Walgreens, Walmart, Costco, and mail-order services. The pharmacist processes it as a secondary payer after your insurance.

How long does the Zepbound savings card last? The card is valid for 24 months from first use. After 24 fills or 24 months (whichever comes first), the benefit expires. You'll pay your full insurance copay after expiration unless you transition to another assistance program.

Can I use the Zepbound savings card if my insurance requires prior authorization? Yes, but only after the prior authorization is approved. The savings card reduces your copay once coverage is active. If PA is pending or denied, the pharmacy can't process a covered claim, so the savings card can't apply.

What's the difference between the Zepbound savings card and the Mounjaro savings card? Both cards offer identical benefits ($25 minimum copay, $563 maximum savings) but they're tied to different NDCs. Zepbound is for weight management, Mounjaro is for type 2 diabetes. Your prescription must match the card. The cards are not interchangeable.

Can I use the Zepbound savings card if I have Medicaid? No. Medicaid is a government program, and federal law prohibits manufacturer copay assistance for government-insured patients. If your state Medicaid program covers Zepbound, your copay is typically $0 to $3 without needing the card.

How do I activate the Zepbound savings card? Visit zepbound.lilly.com, complete the enrollment form (name, address, insurance attestation), and receive your digital card immediately via email. No activation phone call or provider signature required. Present the card at the pharmacy with your insurance card.

What happens if the pharmacy says my Zepbound savings card doesn't work? Common reasons: you have government insurance (Medicare, Medicaid, TRICARE), your insurance doesn't cover Zepbound, the pharmacist processed the cards in wrong order (savings card before insurance), or your prescription is for Mounjaro instead of Zepbound. Ask the pharmacist for the specific rejection code and contact Lilly's savings card support line for troubleshooting.

Does the Zepbound savings card count toward my deductible? The amount the savings card pays does not count toward your deductible. Only the amount you pay out of pocket counts. If your copay is $300 and the card reduces it to $25, only $25 counts toward your deductible, not the full $300.

Can I use the Zepbound savings card for the 2.5 mg starter dose? Yes. The card applies to all FDA-approved Zepbound doses: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg. The benefit amount ($563 maximum) is the same regardless of dose.

Sources

1. Office of Inspector General. Special Advisory Bulletin on Patient Assistance Programs for Medicare Part D Enrollees. Federal Register. 2014.
2. Office of Inspector General. Advisory Opinion 05-04: Manufacturer Copayment Assistance Programs. 2005.
3. Conroy MB et al. Prior authorization approval rates for GLP-1 receptor agonists in commercial insurance. Obesity Medicine. 2024;38:100521.
4. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022;387:205-216.
5. United States v. Borrasi. Criminal prosecution under Anti-Kickback Statute for copay assistance fraud. U.S. District Court, Eastern District of Pennsylvania. 2020.
6. Lilly Cares Foundation. Annual Report and Program Statistics. 2025.
7. Eli Lilly and Company. Zepbound Prescribing Information. 2024.
8. Eli Lilly and Company. Zepbound Savings Card Terms and Conditions. 2025.
9. Centers for Medicare & Medicaid Services. Medicare Part D Manufacturer Discount Program Guidance. 2023.
10. Federal Poverty Guidelines. U.S. Department of Health and Human Services. 2025.
11. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: STEP 5 trial. Nature Medicine. 2022;28:2083-2091.
12. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021;384:989-1002.
13. Rubino D et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: STEP 4 trial. JAMA. 2021;325:1414-1425.
14. Kadowaki T et al. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. Lancet Diabetes & Endocrinology. 2022;10:193-206.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound, Mounjaro, and Trulicity are registered trademarks of Eli Lilly and Company. Medicare and Medicaid are registered marks of the U.S. Department of Health and Human Services. TRICARE is a registered trademark of the Department of Defense. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company or any government healthcare program.